Ghrelin modulates hypothalamic fatty acid-sensing and control of food intake in rainbow trout

Cristina Velasco¹, Marta Librán-Pérez¹, Cristina Otero-Rodríguez¹, Marcos A López-Patiño¹, Jesús M Mínguez¹, José Miguel Cerdá-Reverter² and José L Soengas¹

¹Laboratorio de Fisiología Animal, Departamento de Biología Funcional e Ciencias da Saúde, Facultade de Biología, Universidade de Vigo, 36310 Vigo, Spain
²Departamento de Fisiología de Peces y Biotecnología, Instituto de Acuicultura Torre de la Sal, Consejo Superior de Investigaciones Científicas (CSIC), Castellón, Spain

Abstract

There is no information available on fish as far as the possible effects of ghrelin on hypothalamic fatty acid metabolism and the response of fatty acid-sensing systems, which are involved in the control of food intake. Therefore, we assessed in rainbow trout the response of food intake, hypothalamic fatty acid-sensing mechanisms and expression of neuropeptides involved in the control of food intake to the central treatment of ghrelin in the presence or absence of a long-chain fatty acid such as oleate. We observed that the orexigenic actions of ghrelin in rainbow trout are associated with changes in fatty acid metabolism in the hypothalamus and an inhibition of fatty acid-sensing mechanisms, which ultimately lead to changes in the expression of anorexigenic and orexigenic peptides resulting in increased orexigenic potential and food intake. Moreover, the response to increased levels of oleate of hypothalamic fatty acid-sensing systems (activation), expression of neuropeptides (enhanced anorexigenic potential) and food intake (decrease) were counteracted by the simultaneous treatment with ghrelin. These changes provide evidence for the first time in fish of a possible modulatory role of ghrelin on the metabolic regulation by fatty acid of food intake occurring in the hypothalamus.

Key Words

trout
fish
food intake
ghrelin
fatty acid
hypothalamus

Introduction

In mammals, hypothalamic nuclei from interconnected neuronal circuits react to changes in energy status by regulating the expression of agouti-related protein (AgRP)/neuropeptide Y (NPY) and pro-opio melanocortin (POMC)/cocaine and amphetamine-related transcript (CART), ultimately leading to changes in food intake (Blouet & Schwartz 2010). These neurons integrate information of peripheral signals, such as i) changes in the levels of nutrients/metabolites like glucose, fatty acids and amino acids that are detected through nutrient-sensor mechanisms (Blouet & Schwartz 2010), and ii) changes in the levels of hormones like leptin, ghrelin (GHRL), insulin, glucagon-like peptide 1, cannabinoids, glucocorticoids and adiponectins that are detected by binding of those hormones to their receptors (Dieguez et al. 2009).

The fatty acid-sensing mechanisms detect increases in plasma levels of long-chain fatty acid (LCFA), but not short-chain fatty acid (SCFA) or medium-chain fatty acid
in food intake regulation, this hormone has been also involved in the control of glucose and lipid homeostasis and metabolism (Sangiao-Alvarellos et al. 2010, Ratner et al. 2015) and modulation of hormone release (Carreira et al. 2013), among others (Sato et al. 2014, Müller et al. 2015). GHRL has been also identified in a number of fish species, including rainbow trout (Oncorhynchus mykiss), Japanese eel (Anguilla japonica), sea bass (Dicentrarchus labrax), Atlantic salmon (Salmo salar), zebrafish (Danio rerio), goldfish (Carassius auratus), tilapia (Oreochromis mossambicus) and channel catfish (Ictalurus punctatus) (Kaiya et al. 2008, Kang et al. 2011). It is highly expressed in the gastrointestinal tract, moderately in the brain and to a lower extent in other tissues (Unniappan et al. 2002, Unniappan & Peter 2005, Volkoff et al. 2005). Once octanoylated, GHRL binds to GHS-R1a, which is also expressed in a panel of fish tissues such as the brain (particularly hypothalamus), gastrointestinal tissue, pancreatic cells and liver (Chang & Cheng 2004, Kaiya et al. 2009, Cruz et al. 2010). The role of GHRL in fish is far from elucidated though it has been involved in the control of food intake (Unniappan et al. 2002, Kang et al. 2011, Jönsson 2013), glucose and lipid metabolism (Kaiya et al. 2009, Salmerón et al. 2015) and the modulation of growth hormone and prolactin release (Kaiya et al. 2008). GHRL is accepted as an orexigenic factor in fish (Unniappan et al. 2002, 2004, Matsuda et al. 2006, Shepherd et al. 2007, Miura et al. 2006, 2007, Tinoco et al. 2014), though changes in the expression of neuropeptides involved in the metabolic regulation of food intake have been scarcely studied (Polakof et al. 2011a, Riley 2013, Tinoco et al. 2014, Schroeter et al. 2015). Furthermore, there is no information available in fish regarding the possible effects of GHRL on hypothalamic fatty acid metabolism and the response of fatty acid-sensing systems. Based on the anorectic actions of LCFA like olate in rainbow trout (Librán-Pérez et al. 2012, 2014a), the orexigenic actions of GHRL in fish (Kang et al. 2011), and the fact that plasma GHRL levels increase in rainbow trout after a meal (Pankhurst et al. 2008), especially when fish were fed with a lipid-enriched diet (Jönsson et al. 2007), we hypothesize that the response to raised levels of fatty acid of food intake, hypothalamic fatty acid-sensing mechanisms and expression of neuropeptides involved in the control of food intake might be counteracted by GHRL treatment in rainbow trout.

Therefore, we aimed to elucidate in rainbow trout i) the effects of GHRL on hypothalamic fatty acid metabolism and the response of fatty acid-sensing systems involved in the control of food intake, and ii) the possible...
modulatory effect of GHRL on the effects of raised levels of oleate. Thus, we centrally injected GHRL in the presence or absence of oleate and evaluated food intake, and the mRNA abundance of hypothalamic neuropeptides involved in the nutrient control of food intake, such as AgRP, NPY, POMC and CART as well as CRF, as a peptide involved in the anorectic response to stressful conditions. We also evaluated variables related to putative fatty acid-sensing systems based on i) fatty acid metabolism, such as activities of fatty acid synthase (FAS, EC 2.3.1.85), ATP-citrate lyase (ACLY, EC 4.1.3.8) and CPT1 (EC 2.3.1.21), and mRNA abundance of acetyl-CoA carboxylase (ACC), ACLY, CPT1c and FAS; ii) binding to FAT/CD36 and further modulation of transcription factors, such as mRNA abundance of FAT/CD36, PPARα and SREBP1c; and iii) mitochondrial activity, such as mRNA abundance of mitochondrial uncoupling protein 2a (UCP2a) and inward rectifier K⁺ channel pore type 6.x-like (Kir6.x-like). Finally, we also evaluated changes in other integrative sensors such as mRNA abundance of AMPKα1, SIRT1 and lipoprotein lipase (LPL).

Materials and methods

Fish

Rainbow trout were obtained from a local fish farm (A Estrada, Spain). Fish were maintained for 1 month in 100-l tanks under laboratory conditions and a 12 h light:12 h darkness photoperiod (lights on at 0800 h, lights off at 2000 h) in dechlorinated tap water at 15 °C. Fish weight was 100±2 g. Fish were fed once daily (0900 h) to satiety with commercial dry fish pellets (Dibaq-Diproteg SA, Spain; proximate food analysis was 48% crude protein, 14% carbohydrates, 25% crude fat and 11.5% ash; 20.2 MJ/kg of feed). The experiments described comply with the Guidelines of the European Union Council (2010/63/UE) and of the Spanish Government (RD 55/2013) for the use of animals in research, and were approved by the Ethics Committee of the Universidade de Vigo.

Experimental design

Following 1 month acclimation period, fish were randomly assigned to 100-l experimental tanks. Fish were fasted for 24 h before treatment to ensure basal hormone levels were achieved. On the day of experiment, fish were lightly anaesthetized with 2-phenoxyethanol (Sigma, 0.2% v/v) and weighed. Intracerebroventricular (ICV) administration was performed as previously described (Polakof & Soengas 2008). Briefly, fish were placed on a plexiglass board with Velcro straps adjusted to hold them in place. A 29½-gauge needle attached through a polyethylene cannula to a 10 µl Hamilton syringe was aligned with the 6th pre-orbital bone at the rear of the eye socket, and from this point the syringe was moved through the space in the frontal bone into the third ventricle. The plunger of the syringe was slowly depressed to dispense 1 µl/100 g body mass of vehicle (control), or containing 200 ng of rainbow trout octanoylated 23 amino acid GHRL (synthesized by Bachem according to the sequence published by Kaiya et al. (2003)), 1 µmol oleate (Sigma Chemical Co.), or GHRL+oleate. The vehicle used, saline-HPB, was a mixture (1:1 in vol) of Hanks’ saline and a solution in Hanks’ saline of 45% hydroxypropyl-beta-cyclodextrin (HPB) to a final concentration of 17 mM (Morgan et al. 2004). We used the HPB fraction to safely deliver oleate, and the saline fraction to dissolve GHRL. No effects of HPB alone were noted for any of the parameters assessed (data not shown).

In the first set of experiments, food intake was registered for 3 days before treatment (to evaluate basal level of food intake) and then 6, 24 and 48 h after ICV treatment with saline-HPB alone (control, n=10 for each time point) or containing GHRL (n=10 for each time point), oleate (n=10 for each time point) or GHRL+oleate (n=10 for each time point). After feeding, the uneaten food remaining at the bottom (conical tanks) and feed waste were withdrawn, dried and weighed. The amount of food consumed by all fish in each tank was calculated as previously described as the difference from the feed offered (De Pedro et al. 1998, Polakof et al. 2008a, b). The experiment was repeated four times. Results are shown as the mean±S.E.M. (n=4).

In a second set of experiments, fish were ICV injected with saline-HPB alone (control, n=15 at 2 h, and n=15 at 6 h) or containing GHRL (n=15 at 2 h, and n=15 at 6 h), oleate (n=15 at 2 h, and n=15 at 6 h) or GHRL+oleate (n=15 at 2 h, and n=15 at 6 h) with the same concentrations described above. After 2 or 6 h, fish were lightly anaesthetized with 2-phenoxyethanol (Sigma, 0.2% v/v). Blood was collected by caudal puncture with ammonium-heparinized syringes, and plasma samples were obtained after blood centrifugation, de-proteinized immediately (using 0.6 M perchloric acid) and neutralized (using 1 M potassium bicarbonate) before freezing with liquid nitrogen and storage at −80 °C until further assay. Fish were sacrificed by decapitation and the hypothalami were dissected, snap-frozen and stored at −80 °C. Each time, nine fish per group were used to assess enzyme activities
and metabolite levels whereas the remaining six fish were used for the assessment of mRNA levels by qRT-PCR.

Assessment of metabolite levels and enzyme activities

Levels of fatty acid, total lipid, triglyceride, glucose and lactate in plasma were determined enzymatically using commercial kits (Wako Chemicals, Neuss, Germany, for fatty acid; Spinreact, Barcelona, Spain for total lipid, triglyceride and lactate; Biomerieux, Grenoble, France, for glucose).

Samples used to assess hypothalamic metabolite levels were homogenized immediately by ultrasonic disruption in 7.5 vols of ice-cooled 0.6 M perchloric acid, and neutralized as before. The homogenate was centrifuged (10,000 × g), and the supernatant used to assay tissue metabolites. Tissue fatty acid, total lipid and triglyceride levels were determined enzymatically using commercial kits as described above for plasma samples.

Samples for enzyme activities were homogenized by ultrasonic disruption with 9 vols of ice-cold-buffer consisting of 50 mM Tris (pH 7.6), 5 mM EDTA, 2 mM 1,4-dithiothreitol and a protease inhibitor cocktail (Sigma). The homogenate was centrifuged (10,000 × g) and the supernatant used immediately for enzyme assays. Enzyme activities were determined using a microplate reader INFINITE 200 Pro (Tecan, Männedorf, Switzerland). Reaction rates of enzymes were determined by the increase or decrease in the absorbance of NAD(P)H at 340 nm or, in the case of CPT1 activity, of 5,5′-dithiobis(2-nitrobenzoic acid)-CoA complex at 412 nm. The reactions were started by the addition of supernatant (15 µl) at a pre-established protein concentration, omitting the substrate in control wells (final volume 265–295 µl), and allowing the reactions to proceed at 20 °C for pre-established times (3–10 min). Enzyme activities were normalized to protein levels (mg). Protein was assayed in triplicate in homogenate using microplates according to the bicinchoninic acid method with BSA (Sigma), and the supernatant used to assay tissue metabolites.

mRNA abundance analysis by real-time quantitative RT-PCR

Total RNA was extracted using Trizol reagent (Life Technologies) and subsequently treated with RQ1-DNase (Promega). Two microgram total RNA were reverse-transcribed using Superscript II reverse transcriptase (Promega) and random hexamers (Promega) to obtain ~20 µl. Gene expression levels were determined by real-time quantitative RT-PCR (q-PCR) using the iCycler iQ (BIO-RAD). Analyses were performed on 1 µl cDNA using MAXIMA SYBR Green qPCR Mastermix (Life Technologies), in a total PCR reaction volume of 15 µl, containing 50–500 nM of each primer. mRNA abundance of ACC, ACLY, AMPK, AgRP, CART, CPT1, FAT/CD36, FAS, Kir6.x-like, LPL, NPY, POMC, PPARz, SIRT1, SREBP1c and UCP2a were determined as described in the same species (Ducasse-Cabanot et al. 2007, Kolditz et al. 2008, Polakof et al. 2008c, Cruz-Garcia et al. 2009, Lansard et al. 2009, Conde-Sieira et al. 2010, Polakof et al. 2010, 2011b, Figueiredo-Silva et al. 2012, Librán-Pérez et al. 2013b). Sequences of the forward and reverse primers used for each gene expression are shown in Table 1. Relative quantification of the target gene transcript was done using β-actin gene expression as reference, which was stably expressed in this experiment. Thermal cycling was initiated with incubation at 95 °C for 90 s using hot-start iTaq DNA polymerase activation followed by 35 cycles, each one consisting of heating at 95 °C for 20 s, and specific annealing and extension temperatures for 20 s. Following the final PCR cycle, melting curves were systematically monitored (55 °C temperature gradient at 0.5 °C/s from 55 to 94 °C) to ensure that only one fragment was amplified. Samples without reverse transcriptase and samples without RNA were run for each reaction as negative controls. Relative quantification of the target gene transcript with the β-actin reference gene transcript was made following the Pfaffl (2001) method. This mathematical algorithm computes an expression ratio based on q-PCR efficiency and the crossing point deviation of the unknown sample versus a control group:

$$R = \left( \frac{E_{\text{target gene}}^{\Delta C_{T_{\text{target gene}}}} \text{mean control–mean unknown sample}}{E_{\text{β-actin}}^{\Delta C_{T_{\text{β-actin}}}} \text{mean control–mean unknown sample}} \right)^{1/2}$$

where E is PCR efficiency determined using a standard curve of cDNA serial dilutions (cDNA dilutions from 1/32 up to 1/512) and ΔCT is the crossing point deviation of an unknown sample versus a control.

Statistical analysis

Comparisons among groups were carried out with one-way ANOVA followed by a Student-Newman-Keuls test, and differences were considered statistically significant at P<0.05.
Levels of plasma metabolites are shown in Fig. 1. Levels of fatty acid levels (Fig. 2A) in the oleate group increased compared with control (2 h), GHRL (2 and 6 h) and GHRL+oleate (6 h) groups. Triglyceride levels (Fig. 2B) after 2 h were also higher than all other groups. Finally, no significant changes were observed for mRNA abundance of AgRP (Fig. 4D) after 2 h whereas the value of the oleate group were also higher than that of GHRL group after 6 h of treatment.

Changes in mRNA abundance of parameters related to fatty acid sensing in hypothalamus are shown in Table 2. FAT/CD36 increased in the GHRL group compared with control groups after 2 h whereas the value of the oleate group was higher than that of GHRL group after 6 h. ACC mRNA

Results

Levels of plasma metabolites are shown in Fig. 1. Levels of fatty acid (Fig. 1A), triglyceride (Fig. 1B), glucose (Fig. 1C) and lactate (Fig. 1D) were not affected by treatments. Hypothalamic metabolite levels are shown in Fig. 2. Fatty acid levels (Fig. 2A) in the oleate group increased compared with control (2 h), GHRL (2 and 6 h) and GHRL+oleate (6 h) groups. Triglyceride levels (Fig. 2B) increased in the oleate group at 2 h compared with control and GHRL groups. Total lipid levels (Fig. 2C) compared with control (2 h), GHRL (2 and 6 h) and GHRL+oleate (6 h) groups. The mRNA abundance of NPY (Fig. 4C) was higher in the GHRL group compared with control (2 h), oleate (2 and 6 h) and GHRL+oleate (6 h) groups. The mRNA abundance of AgRP (Fig. 4D) after 2 h was lower in the oleate group compared with the other groups. Finally, no significant changes were observed for mRNA abundance of CRF (Fig. 4E).

Changes in food intake are shown in Fig. 5. GHRL treatment increased food intake compared with control (24 h), oleate (24 and 48 h) and GHRL+oleate (24 and 48 h) groups. Olate treatment decreased food intake compared with control and GHRL groups.

Changes in mRNA abundance of parameters related to fatty acid sensing in hypothalamus are shown in Table 2. FAT/CD36 decreased in the GHRL compared with control groups after 2 h whereas the value of the oleate group was higher than that of GHRL group after 6 h. ACC mRNA

Table 1 Nucleotide sequences of the PCR primers used to evaluate mRNA abundance by RT-PCR (qPCR).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer</th>
<th>Reverse primer</th>
<th>Annealing temperature (°C)</th>
<th>Data base</th>
<th>Accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>GATGGGCCGCAAGAAGACAGCTA</td>
<td>TCGTCCAGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>NM_001124235_1</td>
</tr>
<tr>
<td>ACC</td>
<td>CAGAGTTGGAGTAAAGACCTA</td>
<td>CTCGATCCTTCTCCACT</td>
<td>59</td>
<td>GenBank</td>
<td>CA349411_1</td>
</tr>
<tr>
<td>ACLY</td>
<td>CAGAGATGGGACAGGAAGAG</td>
<td>ATGCATTGCATTTTGAACCA</td>
<td>60</td>
<td>GenBank</td>
<td>CQ40367</td>
</tr>
<tr>
<td>AMPKα1</td>
<td>AAGTGACATGAGGACACCA</td>
<td>CTGCACTTCAAGCTCCCA</td>
<td>60</td>
<td>GenBank</td>
<td>CR376289</td>
</tr>
<tr>
<td>AgRP</td>
<td>AAGAAATGAGGTCATAGCTCG</td>
<td>ACCCACTGGTCCTCCAC</td>
<td>59</td>
<td>GenBank</td>
<td>AF296672</td>
</tr>
<tr>
<td>CART</td>
<td>TGAGGGCGTTTTCACTATCC</td>
<td>ACCCACTGGTCCTCCAC</td>
<td>59</td>
<td>GenBank</td>
<td>Q601124267</td>
</tr>
<tr>
<td>CPT-1c</td>
<td>CTCGCTGTCAAGACTGAGCTG</td>
<td>TCTGTTGTGAGTACGCT</td>
<td>59</td>
<td>GenBank</td>
<td>TC86162</td>
</tr>
<tr>
<td>CRF</td>
<td>CTGGAGCTGTTTGTGACGAT</td>
<td>TGAGGCGTTTTCACTATCC</td>
<td>59</td>
<td>GenBank</td>
<td>Q601124266</td>
</tr>
<tr>
<td>FAT/CD36</td>
<td>ACTTCTGAGCTCCACAGCA</td>
<td>CTGGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>TC86162</td>
</tr>
<tr>
<td>Kir6.x-like</td>
<td>AAAGCGAGCTTCAAGCA</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>LPL</td>
<td>CTGCAGCAGCTTCAAGCA</td>
<td>CTGGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>NPY</td>
<td>GTGACGTGAACACTGAGG</td>
<td>CTGGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>POMC-A1</td>
<td>CTCGCTTCAGCTCAAGCTCACTTC</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>PPARα</td>
<td>GCAAGTTTCTGACGAGCT</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>SIRT-1</td>
<td>CTCAAGTCCAGCTCGACCA</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>SREBP1c</td>
<td>CACCGTATTCTGACGATC</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
<tr>
<td>UCP2a</td>
<td>CTGGCTCACAGAACCCCA</td>
<td>CTCGAGCTGTTTGTGACGAT</td>
<td>59</td>
<td>GenBank</td>
<td>CA346261_1</td>
</tr>
</tbody>
</table>

ACC, Acetyl-CoA carboxylase; ACLY, ATP-citrate lyase; AMPKα1, AMP-activated protein kinase; CART, cocaine- and amphetamine-related transcript; CPT-1, carnitine palmitoyl transferase type 1; CRF, corticotropin-releasing factor; FAS, fatty acid synthetase; FAT/CD36, fatty acid translocase; Kir6.x-like, inward rectifier K+ channel pore type 6-like; LPL, Lipoprotein lipase; NPY, neuropeptide Y; POMC-A1, pro-opio melanocortin A1; PPARα, peroxisome proliferator-activated receptor type α; SIRT-1, sirtuin; SREBP1c, sterol regulatory element-binding protein type 1c; UCP2a, mitochondrial uncoupling protein 2a.
abundance increased in the GHRL group compared with control (6 h), oleate (2 and 6 h) and GHRL+oleate (6 h) groups whereas the GHRL+oleate group was also higher than oleate group after 2 h. ACLY mRNA abundance was higher in the GHRL than in the oleate group after 2 or 6 h, whereas the value of the oleate group was lower than that of control after 6 h. CPT1c value of the oleate group after 6 h was lower than those of control and GHRL groups. The value of FAS in the GHRL group was higher than those of control (2 and 6 h), oleate (2 and 6 h) and GHRL+oleate (6 h) groups whereas the value of the GHRL+oleate group was higher than those of control (2 h), GHRL (6 h) and oleate (2 and 6 h) groups. The mRNA abundance of UCP2a after 2 h decreased in GHRL and oleate groups compared with control and GHRL+oleate groups. The value of Kir6.x-like in the oleate group was lower than in the other groups either after 2 or 6 h of treatment (except GHRL+oleate after 6 h). The mRNA abundance of PPARα after 6 h of treatment was lower in the GHRL and GHRL+oleate groups compared with control group. The mRNA abundance of SREBP1c after 6 h of treatment was lower in the oleate and GHRL+oleate groups compared with GHRL group after 2 h, whereas the GHRL group was higher than that of control and oleate groups 6 h after treatment. The value of SIRT1 after 2 h was higher in the oleate than in the remaining groups, whereas after 6 h the values of all treated groups were lower than those of controls. Finally, LPL mRNA abundance decreased in all treated groups compared with controls either after 2 or 6 h of treatment.

Figure 1
Levels of fatty acid (A), triglyceride (B), glucose (C) and lactate (D) in plasma of rainbow trout 2 or 6 h after intracerebroventricular administration of 1 μl/100 g body mass of saline-HPB alone (Control, C) or containing 200 ng of rainbow trout ghrelin (GHRL), or 1 μmol oleate (OL), or GHRL+oleate (GHRL+OL). Each value is the mean ± S.E.M. of n = 15 fish per treatment. Different letters indicate significant differences (P < 0.05) from different groups.

Figure 2
Levels of fatty acid (A), triglyceride (B) and total lipid (C) in hypothalamus of rainbow trout 2 or 6 h after intracerebroventricular administration of 1 μl/100 g body mass of saline-HPB alone (Control, C) or containing 200 ng of rainbow trout ghrelin (GHRL), or 1 μmol oleate (OL), or ghrelin + oleate (GHRL+OL). Each value is the mean ± S.E.M. of n = 9 fish per treatment. Different letters indicate significant differences (P < 0.05) from different groups.
Discussion

Oleate treatment activates fatty acid-sensing systems and inhibit food intake

The central treatment with oleate alone resulted in hypothalamic changes of parameters related to fatty acid sensing. These changes include increased levels of fatty acid, triglyceride and total lipid, decreased activities of CPT1 and ACLY, and decreased mRNA abundance of ACLY, CPT1c, UCP2a and Kir6.x-like, and are indicative of the activation of different fatty acid-sensing systems in response to raised levels of oleate. The activation of these systems is also associated with the increased mRNA abundance of the anorexigenic peptides POMC and CART and the decreased mRNA abundance of the orexigenic peptides AgRP and NPY. The resultant increased anorexigenic potential agrees with the decreased food intake observed in oleate-treated fish. All these changes are in agreement with previous studies carried out in rainbow trout (Librán-Pérez et al. 2014a), which together with the absence of changes in plasma levels of metabolites (suggesting the absence of stress) validate the experimental design.

GHRL treatment inhibits fatty acid-sensing systems increasing hypothalamic orexigenic potential and stimulating food intake

Central GHRL treatment did not affect levels of metabolites in plasma. This lack of changes is in agreement with the absence of changes in glycaemia in the same
species after ICV GHRL treatment (Polakof et al. 2011a), which further validates the experimental design since treatments are reflecting central and not peripheral mechanisms. Thus, in other studies in fish in which GHRL treatment was through, i.p. injection changes in plasma glucose levels were noted (Schwandt et al. 2010). Furthermore, the lack of changes in fatty acid levels is in agreement with that reported in mice under a comparable ICV treatment (Schroeter et al. 2015). GHRL treatment did not affect levels of fatty acid, triglyceride or total lipid in the hypothalamus. This is in contrast to the mammalian model, where ICV GHRL treatment resulted in increased hypothalamic fatty acid levels (Andrews et al. 2008).

GHRL treatment did not affect food intake 6 h after ICV treatment, but feeding levels increased 24 h after treatment and this trend remained (though no significance was found) up to 48 h after treatment. The orexigenic effect is in agreement with that observed in most fish species after IP or ICV GHRL treatments (Unniappan et al. 2002, 2004, Matsuda et al. 2006, Miura et al. 2006, 2007, Tinoco et al. 2014), and is in line to the effect of this peptide in other vertebrates, including mammals (López et al. 2008, Sangiao-Alvarelos et al. 2010, Velásquez et al. 2011, Martins et al. 2013, Stark et al. 2015). It is surprising that GHRL did not also increase food intake 6 h after treatment. We have no explanation for this lack of effect, which could relate to the fact that food intake was measured per group and not individually. Our results differ from those reported previously in rainbow trout showing an anorectic effect of ICV-administrated rainbow trout GHRL (Jönsson et al. 2010). In their study, Jönsson et al. (2010) attributed the anorectic effects of GHRL to the observed increase in the mRNA abundance of hypothalamic CRF. In our study, we have not observed any change in the hypothalamic CRF expression. We do not have an explanation for this controversial finding, but increased CRF levels in the study of Jönsson et al. (2010) suggest an activation of the HPI axis. Therefore, the result observed by Jönsson et al. (2010) could result from an interaction between GHRL treatment and central stress response. Accordingly, tilapia treated with cortisol showed a decrease in plasma GHRL levels and food intake, demonstrating an interaction between stress and GHRL (Upton & Riley 2013).

Considering the changes observed in the mRNA abundance of neuropeptides involved in the metabolic control of food intake, we observed that GHRL induced decreased expression levels of the anorexigenic peptides POMC and CART and increased values of the orexigenic peptides AgRP and NPY. These changes are indicative of an orexigenic response in agreement with the changes observed in food intake. In previous studies in fish, only NPY and POMC responses to GHRL treatment have been studied. Results reported controversial conclusions showing GHRL-induced increase (Riley 2013), decrease (Polakof et al. 2011a) or no effects (Tinoco et al. 2014) on central NPY expression, whereas no changes were observed in POMC hypothalamic expression in channel catfish after IP GHRL treatment (Schroeter et al. 2015). This is the first study in which the GHRL effect on the four main neuropeptides involved in the metabolic regulation of food intake have been assessed simultaneously. The observed changes are in concordance with those previously observed in mammals in which central GHRL administration resulted in consistent increases of NPY and AgRP expression (Andrews et al. 2008, Sangiao-Alvarelos et al. 2010, Martins et al. 2013, Stark et al. 2015) and, occasionally, in decreased POMC and CART mRNA levels (Velásquez et al. 2011).

Effects of GHRL on central lipid metabolism or fatty acid sensing in fish remains unexplored. Our results show differential effects depending on the fatty acid-sensing mechanism studied. The fatty acid-sensing system related to fatty acid metabolism displayed changes opposed to those previously described after central oleate or octanoate...
Table 2 mRNA levels in hypothalamus of rainbow trout 2 or 6 h after intracerebroventricular administration of 1 μl/100 g body mass of saline-HPB alone (Control, C) or containing 200 ng of rainbow trout ghrelin (GHRL), or 1 μmol oleate (OL), or ghrelin + oleate (GHRL + OL). Data represent mean ± S.E.M. of six measurements. Gene expression results are referred to control group and are normalized by 18s expression. Different symbols indicate significant differences (*0.05) from different groups.

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Treatment</th>
<th>FAT/CD36</th>
<th>ACC</th>
<th>FAS</th>
<th>MITO Uncoupling</th>
<th>Kir6.x-like</th>
<th>SIRT1</th>
<th>PPARG</th>
<th>SREBP1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 h</td>
<td>C</td>
<td>1.00 ± 0.05</td>
<td>1.00 ± 0.11</td>
<td>1.00 ± 0.08</td>
<td>1.00 ± 0.17</td>
<td>1.00 ± 0.10</td>
<td>1.00 ± 0.14</td>
<td>1.00 ± 0.10</td>
<td>1.00 ± 0.10</td>
</tr>
<tr>
<td></td>
<td>GHRL</td>
<td>0.82 ± 0.08</td>
<td>1.27 ± 0.04</td>
<td>1.22 ± 0.19</td>
<td>1.47 ± 0.12</td>
<td>0.55 ± 0.05</td>
<td>0.46 ± 0.11</td>
<td>1.25 ± 0.07</td>
<td>1.03 ± 0.10</td>
</tr>
<tr>
<td></td>
<td>GHRL + OL</td>
<td>1.29 ± 0.09</td>
<td>1.46 ± 0.13</td>
<td>1.55 ± 0.11</td>
<td>1.54 ± 0.17</td>
<td>0.60 ± 0.20</td>
<td>1.18 ± 0.24</td>
<td>1.18 ± 0.24</td>
<td>1.87 ± 0.10</td>
</tr>
<tr>
<td>6 h</td>
<td>C</td>
<td>1.00 ± 0.11</td>
<td>1.00 ± 0.09</td>
<td>1.00 ± 0.08</td>
<td>1.00 ± 0.07</td>
<td>1.00 ± 0.04</td>
<td>1.10 ± 0.15</td>
<td>0.56 ± 0.04</td>
<td>0.76 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>GHRL</td>
<td>1.00 ± 0.11</td>
<td>1.00 ± 0.09</td>
<td>1.00 ± 0.08</td>
<td>1.00 ± 0.07</td>
<td>1.00 ± 0.04</td>
<td>1.10 ± 0.15</td>
<td>0.56 ± 0.04</td>
<td>0.76 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>GHRL + OL</td>
<td>1.29 ± 0.09</td>
<td>1.46 ± 0.13</td>
<td>1.55 ± 0.11</td>
<td>1.54 ± 0.17</td>
<td>0.60 ± 0.20</td>
<td>1.18 ± 0.24</td>
<td>1.18 ± 0.24</td>
<td>1.87 ± 0.10</td>
</tr>
</tbody>
</table>

We hypothesized that the effects of oleate treatment on hypothalamic function and food intake might be counteracted by the simultaneous treatment with GHRL, indicating a modulatory role of this peptide in the metabolic

**GHRL treatment in the presence of oleate counteracts the effects of oleate on the activation of fatty acid-sensing systems, the expression of hypothalamic neuropeptides and food intake**

We hypothesized that the effects of oleate treatment on hypothalamic function and food intake might be counteracted by the simultaneous treatment with GHRL, indicating a modulatory role of this peptide in the metabolic...
regulation of food intake. Indeed, the oleate-induced inhibition of food intake levels is counteracted by GHRL administration. To our knowledge, this is the first demonstration for a role of GHRL in fatty acid regulation of feeding. The effects of the joint treatment on food intake are in line with those observed in the expression of hypothalamic neuropeptides. Overall, oleate increased anorexigenic potential by decreasing NPY and AgRP hypothalamic expression and increasing mRNA abundance of POMC and CART.

GHRL treatment also counteracted changes elicited by oleate treatment in several of the fatty acid-sensing mechanisms. Thus, in the fatty acid-sensing mechanism based on fatty acid metabolism, oleate treatment increased levels of fatty acid, triglyceride and total lipid, and this effect was antagonized by GHRL treatment. A similar counteractive effect of GHRL was also observed when studying ACC, ACLY and FAS expression. However, the responses of the parameters related to the fatty acid-sensing systems based on FAT/CD36 were not affected by the simultaneous treatment. The system related to mitochondrial activity displayed in the fish treated with GHRL and oleate values similar to those of controls and different to those observed in the group treated only with oleate, as observed in mRNA abundance of UCP2a and Kir6.x-like. These changes are effectively suggesting that GHRL counteracts the response elicited by oleate at least in two of the fatty acid-sensing systems assessed. As far as we are aware, this kind of experimental approach had not been conducted before, even in mammalian models. Therefore, these results bring up interesting questions regarding the mechanisms through which GHRL binding to GHS-R1a modulates the changes in cellular signalling pathways previously induced by activation of fatty acid-sensing systems. In this way, we recently demonstrated that feeding rainbow trout with a lipid-enriched diet resulted in hypothalamic in the activation of AMPK, mTOR and Akt (Librán-Pérez et al. 2015b). These molecules, among others, could be involved in the changes in cellular signalling elicited by fatty acid-sensing systems, which could be also modulated by GHRL action. These counteractive effects of GHRL and fatty acid-sensing mechanisms deserve further study.

In summary, we have demonstrated, for the first time in a non-mammalian vertebrate, that the orexigenic actions of GHRL in fish are associated with changes in fatty acid metabolism and an inhibition of fatty acid-sensing systems in the hypothalamus, which ultimately lead to changes in the expression of anorexigenic and orexigenic peptides, resulting in increased orexigenic potential and food intake. Moreover, the response to increased levels of oleate of hypothalamic fatty acid-sensing systems (activation), expression of neuropeptides (enhanced anorexigenic potential) and food intake (decrease) were counteracted by the simultaneous treatment with GHRL. These changes provide evidence, again for the first time, of a possible modulatory role of GHRL on the metabolic regulation of food intake occurring in the hypothalamus of fish. The mechanisms observed are similar to those known in mammals in some cases but not in others, suggesting a new model of hypothalamic integration of peripheral signals like levels of metabolites (fatty acid) and hormones (GHRL) involved in the regulation of food intake. Further studies are necessary to elucidate how these peripheral signals are integrated in hypothalamus.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements
This study was supported by research grants from Ministerio de Economía y Competitividad (Spain) and European Fund for Regional Development to JL S (AGL2013-46448-C1-1-R and FEDER) and JM C-R (AGL2013-46448-C1-3-R and FEDER). M L-P and C O-R were recipients of pre-doctoral fellowships from the Ministerio de Economía y Competitividad (BES-2011-043394 and BES-2014-068040 respectively).

References


Librán-Pérez M, López-Patiño MA, Míguez JM & Soengas JL 2013a Oleic acid and octanoic acid sensing capacity in rainbow trout Oncorhynchus mykiss is direct in hypothalamus and Brockmann bodies. *PLoS ONE* **8** e59507. (doi:10.1371/journal.pone.0059507)

Librán-Pérez M, López-Patiño MA, Míguez JM & Soengas JL 2013b In vitro response of putative fatty acid-sensing systems in rainbow trout liver to increased levels of oleate or octanoate. *Comparative Biochemistry and Physiology. A, Comparative Physiology* **165** 288–294. (doi:10.1016/j.cbpa.2013.03.024)


Received in final form 9 October 2015
Accepted 12 October 2015
Accepted Preprint published online 12 October 2015